Envestnet Asset Management Inc. Has $171.91 Million Stock Holdings in Becton, Dickinson and Company $BDX

Envestnet Asset Management Inc. cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 998,030 shares of the medical instruments supplier’s stock after selling 22,595 shares during the period. Envestnet Asset Management Inc. owned about 0.35% of Becton, Dickinson and Company worth $171,911,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Diversified Trust Co raised its holdings in Becton, Dickinson and Company by 4.7% during the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier’s stock worth $272,000 after purchasing an additional 53 shares during the last quarter. Bill Few Associates Inc. raised its holdings in Becton, Dickinson and Company by 0.7% during the 2nd quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock worth $1,362,000 after purchasing an additional 55 shares during the last quarter. Meadow Creek Wealth Advisors LLC raised its holdings in Becton, Dickinson and Company by 5.4% during the 1st quarter. Meadow Creek Wealth Advisors LLC now owns 1,161 shares of the medical instruments supplier’s stock worth $266,000 after purchasing an additional 59 shares during the last quarter. Stephens Inc. AR raised its holdings in Becton, Dickinson and Company by 0.3% during the 1st quarter. Stephens Inc. AR now owns 18,578 shares of the medical instruments supplier’s stock worth $4,255,000 after purchasing an additional 59 shares during the last quarter. Finally, Plancorp LLC raised its holdings in Becton, Dickinson and Company by 4.1% during the 1st quarter. Plancorp LLC now owns 1,499 shares of the medical instruments supplier’s stock worth $343,000 after purchasing an additional 59 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on BDX. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $211.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, October 16th. Morgan Stanley lifted their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Finally, Wells Fargo & Company lifted their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Hold” and a consensus target price of $205.40.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $187.02 on Tuesday. The firm has a market capitalization of $53.61 billion, a PE ratio of 33.64, a price-to-earnings-growth ratio of 1.45 and a beta of 0.25. The firm has a fifty day simple moving average of $189.76 and a two-hundred day simple moving average of $183.63. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The business had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last three months, insiders have sold 1,838 shares of company stock worth $348,392. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.